[Correspondence] Power, dose, and fosfomycin in the SCOUT trial – Authors' reply | ClinicLens
We thank Shankar Biswas and colleagues for their interest in the SCOUT trial.1 Although the study was underpowered, as discussed in the Article, the direction and magnitude of the observed effects warrant consideration. Among women with a positive baseline urine culture, a 5-day
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.